Geographic Segments

3 Months Ended

Sep. 30, 2017

Geographic Segments

Geographic Segments

10.Geographic Segments

Immunomedics manages its operations as one line of business of researching, developing, manufacturing and marketing biopharmaceutical products, particularly antibody-based products for cancer, autoimmune and other serious diseases, and it currently reports as a single industry segment. Immunomedics conducts its research and development activities primarily in the United States. Immunomedics markets and sells LeukoScan® throughout Europe and in certain other countries outside the United States.

The following table presents financial information based on the geographic location of the facilities of Immunomedics as of and for the three -months ended September 30, 2017 and 2016, respectively ($ in thousands):

	As of and for the three months ended
	September 30, 2017
	United
	States		Europe		Total
Total assets	$	151,917	$	1,442	$	153,359
Property and equipment, net		5,877		88		5,965
Revenues		164		526		690
Loss before taxes		(118,752)		(10)		(118,762)

	As of and for the three months ended
	September 30, 2016
	United
	States		Europe		Total
Total assets	$	39,341	$	1,268	$	40,609
Property and equipment, net		4,405		73		4,478
Revenues		144		598		742
Loss before taxes		(16,100)		(129)		(16,229)